Skip to main content
Journal cover image

Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome

Publication ,  Conference
Snyder, B; Bomba, D; Harvey, K; Anderl, J; Kirk, C; Wang, J; Fan, RA; Goel, N
Published in: ARTHRITIS & RHEUMATOLOGY
October 1, 2019

Duke Scholars

Published In

ARTHRITIS & RHEUMATOLOGY

EISSN

2326-5205

ISSN

2326-5191

Publication Date

October 1, 2019

Volume

71

Publisher

WILEY

Related Subject Headings

  • 3204 Immunology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Snyder, B., Bomba, D., Harvey, K., Anderl, J., Kirk, C., Wang, J., … Goel, N. (2019). Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome. In ARTHRITIS & RHEUMATOLOGY (Vol. 71). WILEY.
Snyder, Ben, Darrin Bomba, Ken Harvey, Janet Anderl, Christopher Kirk, Jinhai Wang, R Andrea Fan, and Niti Goel. “Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome.” In ARTHRITIS & RHEUMATOLOGY, Vol. 71. WILEY, 2019.
Snyder B, Bomba D, Harvey K, Anderl J, Kirk C, Wang J, et al. Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome. In: ARTHRITIS & RHEUMATOLOGY. WILEY; 2019.
Snyder B, Bomba D, Harvey K, Anderl J, Kirk C, Wang J, Fan RA, Goel N. Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome. ARTHRITIS & RHEUMATOLOGY. WILEY; 2019.
Journal cover image

Published In

ARTHRITIS & RHEUMATOLOGY

EISSN

2326-5205

ISSN

2326-5191

Publication Date

October 1, 2019

Volume

71

Publisher

WILEY

Related Subject Headings

  • 3204 Immunology
  • 3202 Clinical sciences